India and Israeli collaborate on research in treatment of OSD Print

Israel-based Ocular Discovery and the All India Institute of Medical Sciences (AIIMS) in New Delhi have announced the launch of a novel research partnership investigating the mechanism of action of the drug Dipyridamole for various Ocular Surface Disorders (OSD).

Globally prescribed Dipyridamole, which has been used in the treatment of cardiovascular conditions for over 50 years, is already approved and available in Israel for the relief of various ocular conditions and disorders. The drug has shown marked symptomatic benefit in patients with pterygium and related dryeye symptoms, and also offers accessible and efficient delivery of the medication.

The research collaboration, led by Dr T. Velpandian, AIIMS, and Moshe Rogosnitzky, Ocular Discovery, seeks to investigate the effectiveness in the treatment and optimise dosage as a viable treatment option in the country.

(Issue May 2019)